AZN250110C73000
- 0.16
- 0.000.00%
AstraZeneca Newsroom
TD Cowen Maintains AstraZeneca(AZN.US) With Buy Rating
AstraZeneca (AZN) Gets a Buy From TD Cowen
BOCOM INTL: Maintains Hutchmed (China) 'Buy' rating, Target Price raised to 44 HKD.
BOCOM INTL released a research report stating that it maintains a "Buy" rating for Hutchmed (China) (00013), believing that the transaction conditions are reasonable and favorable for the company's long-term development. The earnings forecast has been adjusted, and the DCF Target Price has been raised to 44 Hong Kong dollars. The company has made continuous key progress in the development of pipelines in the mid to late stage, with relevant catalysts to look forward to in 2025, including: 1) Based on the success of the SAVANNAH study, partner AstraZeneca will soon submit the first overseas NDA for Savolitinib to the FDA (2/3 LMET abnormal treatment-resistant NSCLC); 2) China Phase III SACHI study.
U.S. stock market close: Inflation concerns lead to a decline in all indexes, NVIDIA fell 6% after reaching a new high.
① The Nasdaq China Golden Dragon Index fell by 0.2%, with China Concept Stocks showing mixed results; ② NVIDIA launched its personal computing product Project DIGITS; ③ XPENG Huaitian: Flying cars will be mass-produced and delivered in 2026; ④ Vaccine stocks soared, with Moderna rising nearly 12% and Novavax increasing by nearly 11%.
J&J Lung Cancer Treatment Extends Lives Versus AstraZeneca Drug | NYSE:JNJ
Unusual Options Activity: BP, TPR and Others Attract Market Bets, BP V/OI Ratio Reaches 156.3
J&J Rybrevant/Lazcluze Combo Bests AstraZeneca's Tagrisso in NSCLC
Johnson & Johnson Reports 'Statistically Significant' Data From Trial of Rybrevant, Lazcluze Combination to Treat Lung Cancer
Express News | Refile-Buzz-Obesity Drugs, M&a Among Key Pharma Drivers for 2025, Berenberg Says
Asher Bio Announces Clinical Supply Agreement With AstraZeneca To Enable Evaluation Of Etakafusp Alfa In Combination With Rilvegostomig In A Global Phase 1b/2 Study In Non-Small Cell Lung Cancer
Berenberg Maintains AstraZeneca's Rating on Promising 2025 Pipeline
FDA Issues First Draft Guidance on Use of AI in Drug, Medical Device Development
Vaccine Stocks Gain Amid Uptick in Flu, COVID-19, RSV
AstraZeneca Stock Down Almost 14% in 3 Months: Time to Sell?
AstraZeneca (AZN) Gets a Buy From J.P. Morgan
SA Asks: Which Biotechs Are Most Likely to Be Acquired Near-term?
AstraZeneca PLC Stock Flat Friday
AstraZeneca (AZN.US) has initiated a Phase III clinical trial for the PD-1/TIGIT dual antibody.
AstraZeneca (AZN.US) has launched Phase III clinical trials for its PD-1/TIGIT dual antibody.
AstraZeneca Call Volume Above Normal and Directionally Bullish
Unusual Options Activity: NCLH, AZN and Others Attract Market Bets, NCLH V/OI Ratio Reaches 55.6